Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Bausch & Lomb ZyLET Clears FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Loteprednol/tobramycin ophthalmic will be marketed by sales force that had been promoting the conjunctivitis agent Optivar.

You may also be interested in...



Bausch & Lomb Collaborates With Galapagos On Ophthalmic Disease Candidates

Eye health company joins long list of pharmaceutical firms partnering with Galapagos in past year.

Bausch & Lomb Collaborates With Galapagos On Ophthalmic Disease Candidates

Eye health company joins long list of pharmaceutical firms partnering with Galapagos in past year.

Bausch & Lomb Will Conduct ZyLET Phase IV Study In 60 Young Children

Pediatric study is B&L’s only postmarketing commitment for the combination ophthalmic, FDA’s approval letter states. The company is expected to launch ZyLET in the first quarter of 2005.

Related Content

Topics

UsernamePublicRestriction

Register

ID1135947

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel